Bayard L. Powell

27.4k total citations · 5 hit papers
260 papers, 14.2k citations indexed

About

Bayard L. Powell is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Bayard L. Powell has authored 260 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Hematology, 102 papers in Molecular Biology and 73 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Bayard L. Powell's work include Acute Myeloid Leukemia Research (164 papers), Acute Lymphoblastic Leukemia research (71 papers) and Chronic Myeloid Leukemia Treatments (49 papers). Bayard L. Powell is often cited by papers focused on Acute Myeloid Leukemia Research (164 papers), Acute Lymphoblastic Leukemia research (71 papers) and Chronic Myeloid Leukemia Treatments (49 papers). Bayard L. Powell collaborates with scholars based in United States, Germany and Canada. Bayard L. Powell's co-authors include Richard A. Larson, Charles A. Schiffer, Richard M. Stone, Clara D. Bloomfield, Jonathan E. Kolitz, Krzysztof Mrózek, Guido Marcucci, Andrew J. Carroll, Michael A. Caligiuri and Philip Schulman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Bayard L. Powell

245 papers receiving 13.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

2002 1.3k citations Richard M. Stone, Bayard L. Powell et al. Journal of Clinical Oncology profile →
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

1994 1.0k citations Bayard L. Powell, Joseph O. Moore et al. profile →
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

2006 893 citations Bayard L. Powell, Richard M. Stone et al. profile →
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

2014 595 citations Meir Wetzler, Bayard L. Powell et al. Blood profile →
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

2010 548 citations Guido Marcucci, Kati Maharry et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bayard L. Powell United States	60	9.7k	5.7k	3.3k	2.9k	2.8k	260	14.2k
Mikkael A. Sekeres United States	58	9.1k 0.9×	4.6k 0.8×	1.7k 0.5×	4.3k 1.5×	1.7k 0.6×	626	12.5k
Hervé Dombret France	67	13.5k 1.4×	7.2k 1.3×	6.1k 1.9×	3.7k 1.3×	4.1k 1.5×	377	18.9k
Daniel J. DeAngelo United States	60	9.0k 0.9×	6.2k 1.1×	4.3k 1.3×	3.9k 1.3×	4.3k 1.5×	444	16.3k
Sergio Amadori Italy	58	9.9k 1.0×	4.1k 0.7×	3.0k 0.9×	3.7k 1.3×	3.4k 1.2×	363	15.5k
Meir Wetzler United States	48	5.0k 0.5×	3.0k 0.5×	1.9k 0.6×	2.1k 0.7×	2.1k 0.8×	245	8.6k
Mark R. Litzow United States	70	11.9k 1.2×	5.5k 1.0×	4.9k 1.5×	4.9k 1.7×	4.8k 1.7×	597	18.9k
Jacob M. Rowe Israel	59	7.9k 0.8×	3.0k 0.5×	5.6k 1.7×	1.9k 0.6×	3.0k 1.1×	317	12.9k
Norbert Vey France	52	7.1k 0.7×	3.7k 0.6×	2.3k 0.7×	2.2k 0.8×	2.4k 0.9×	402	10.6k
Alan F. List United States	68	15.4k 1.6×	8.3k 1.4×	2.5k 0.8×	6.5k 2.2×	4.2k 1.5×	621	21.9k
Selina M. Luger United States	47	5.4k 0.6×	2.9k 0.5×	3.2k 1.0×	1.1k 0.4×	2.9k 1.1×	304	9.7k

Countries citing papers authored by Bayard L. Powell

Since Specialization

Citations

This map shows the geographic impact of Bayard L. Powell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bayard L. Powell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bayard L. Powell more than expected).

Fields of papers citing papers by Bayard L. Powell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bayard L. Powell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bayard L. Powell. The network helps show where Bayard L. Powell may publish in the future.

Co-authorship network of co-authors of Bayard L. Powell

This figure shows the co-authorship network connecting the top 25 collaborators of Bayard L. Powell. A scholar is included among the top collaborators of Bayard L. Powell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bayard L. Powell. Bayard L. Powell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klepin, Heidi D., Janet A. Tooze, W. Jack Rejeski, et al.. (2025). Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia. Blood Advances. 9(20). 5152–5163.

Nicolet, Deedra, Daelynn R. Buelow, Shelley Orwick, et al.. (2025). Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia. 39(3). 623–631. 1 indexed citations

Solomon, Scott R., Bayard L. Powell, Catherine Lai, et al.. (2024). CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial. Cancers. 16(5). 915–915.

Kohlschmidt, Jessica, Krzysztof Mrózek, Deedra Nicolet, et al.. (2023). Association of social deprivation with survival in younger adult patients with AML: an Alliance study. Blood Advances. 7(15). 4019–4023. 5 indexed citations

Mrózek, Krzysztof, Jessica Kohlschmidt, James S. Blachly, et al.. (2023). Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 37(4). 788–798. 31 indexed citations

Bhatnagar, Bhavana, Jessica Kohlschmidt, Shelley Orwick, et al.. (2023). Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Advances. 7(16). 4671–4675. 1 indexed citations

Nicolet, Deedra, Krzysztof Mrózek, Christopher J. Walker, et al.. (2023). Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients. Blood. 142(Supplement 1). 2954–2954.

Anderson, Rebecca G., Lance D. Miller, Scott Isom, et al.. (2022). Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature Communications. 13(1). 1673–1673. 28 indexed citations

Epstein‐Peterson, Zachary D., Andriy Derkach, Susan M. Geyer, et al.. (2022). Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances. 6(11). 3433–3439. 7 indexed citations

10.

Pardee, Timothy S., Rebecca G. Anderson, Scott Isom, et al.. (2018). A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 24(9). 2060–2073. 80 indexed citations

11.

Bill, Marius, Dario Veneziano, Jessica Kohlschmidt, et al.. (2018). Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood. 132(Supplement 1). 89–89. 2 indexed citations

12.

Walker, Christopher J., Jessica Kohlschmidt, Krzysztof Mrózek, et al.. (2017). No evidence for microsatellite instability in acute myeloid leukemia. Leukemia. 31(6). 1474–1476. 9 indexed citations

13.

Eisfeld, Ann‐Kathrin, Jessica Kohlschmidt, Krzysztof Mrózek, et al.. (2017). Mutation Patterns Identify Adult Patients with De Novo Acute Myeloid Leukemia (AML) Aged 60 Years or Older Who Respond Favorably to Standard Chemotherapy: an Analysis of Alliance Studies. Blood. 130. 103–103.

14.

Powell, Bayard L., et al.. (2017). Acute Myeloid Leukemia in Pregnancy. Blood. 130. 5035–5035.

15.

Pardee, Timothy S., Scott Isom, Leslie R. Ellis, et al.. (2017). Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML. Blood. 130. 2626–2626. 1 indexed citations

16.

Eisfeld, Ann‐Kathrin, Jessica Kohlschmidt, Krzysztof Mrózek, et al.. (2017). Neurofibromin 1 gene Mutations Are Recurrent Events in Adult Patients with Acute Myeloid Leukemia (AML), Associate with Poor Outcome and Refine the Adverse European Leukemianet (ELN) Risk Category. Blood. 130. 186–186.

17.

Pardee, Timothy S., King Lee, John Luddy, et al.. (2014). A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research. 20(20). 5255–5264. 91 indexed citations

18.

Becker, Heiko, Guido Marcucci, Kati Maharry, et al.. (2009). Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 28(4). 596–604. 241 indexed citations

19.

Marcucci, Guido, Kati Maharry, Michael D. Radmacher, et al.. (2008). Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 26(31). 5078–5087. 224 indexed citations

20.

Buss, David H., Bayard L. Powell, Michael O’Connor, et al.. (1996). Usefulness and limitations of serum and urine lysozyme levels in the classification of acute myeloid leukemia: An analysis of 208 cases. Leukemia Research. 20(6). 467–472. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact